07630.HK
Impact Therap-b
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 15.59
+4.07%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -86.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -60.0%
- EBITDA
- -16.9%
- EBIT
- -10.5%
- Net income
- -16.0%
- EPS
- +16.7%
- Free cash flow
- -10.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025